Ebiratide
Also known as: ACTH(4-9) amide analogue, Ebiratide, Hoe 427
Source Ebiratide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ebiratide (also known as Hoe 427) is a synthetic hexapeptide analogue of ACTH(4-9). It was investigated primarily for its neurotrophic and neuroprotective properties, including potential enhancement of learning, memory, and nerve regeneration. Unlike full-length ACTH, ebiratide has minimal steroidogenic activity and acts centrally. Research interest focused on cognitive enhancement and peripheral neuropathy, but it did not advance to approved clinical use.
Mechanism of Action
Synthetic analogue of ACTH(4-9) that acts on melanocortin receptors (MC1R, MC3R, MC4R) and potentially other CNS receptors; modulates neurotrophic and cognitive processes without significant adrenocortical stimulation.
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Cognitive enhancement / memory improvementNeurologicalLow
- Attention and concentration improvementCognitiveLow
- Peripheral nerve regenerationNeurologicalLow
Contraindications
- Known hypersensitivity to ACTH analoguesAllergyHigh
Adverse Effects
- Transient blood pressure changesCardiovascularRare
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- CorticosteroidsLow
Population Constraints
- Patients with adrenal tumorsOncologyRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedDeveloped by Hoechst (Germany) but did not reach marketing authorization; research compound.
- United StatesUnapprovedNever submitted for or received FDA approval; research use only.
- United KingdomUnapprovedNo MHRA approval; research use only.
Ebiratide has not received regulatory approval in any major jurisdiction. It remains a research compound studied in preclinical and early clinical settings.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ebiratide?
Ebiratide (also known as Hoe 427) is a synthetic hexapeptide analogue of ACTH(4-9). It was investigated primarily for its neurotrophic and neuroprotective properties, including potential enhancement of learning, memory, and nerve regeneration. Unlike full-length ACTH, ebiratide has minimal steroidogenic activity and acts centrally. Research interest focused on cognitive enhancement and peripheral neuropathy, but it did not advance to approved clinical use.
What is Ebiratide used for?
Ebiratide is educationally associated with: Neuroprotection, Cognitive enhancement / memory improvement, Attention and concentration improvement, Peripheral nerve regeneration. Educational only — not medical advice.
How is Ebiratide administered?
Recorded routes of administration: Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of Ebiratide?
Reported adverse effects include: Transient blood pressure changes, Injection site reactions, Headache, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ebiratide?
Recorded contraindications: Known hypersensitivity to ACTH analogues. Consult a qualified clinician before use.